Skip to content
value.today

VolitionRx Limited

VNRX
$7 Mmarket cap on Oct 30, 2026-92.1% since Jan 2024
1M
-13.0%
Compare
World rank
#26,406
Revenue
$2 M
For year ending December-2025
Net income
$-23 M
-1350.3% margin
SEC filing
Employees
—

VolitionRx Limited in brief

VolitionRx Limited is a listed company in the Diagnostics and Research industry, based in Henderson, Nevada, USA. It was founded in 1998. Its market value was $7 M on 30 October 2026, which makes it the 26,406th largest listed company in the world and the 4,351st largest in the USA on this site. In the year to December 2025 it had sales of $2 M and a net loss of $23 M. Cameron John Reynolds is its chief executive. Its shares trade under the symbol VNRX (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About VolitionRx Limited

Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing its innovative family of simple, easy to use, cost-effective blood tests.

Volition is a multi-national epigenetics company. It has patented technologies that use chromosomal structures, such as nucleosomes, and transcription factors as biomarkers in cancer and other diseases. The tests in the Company’s product portfolio detect certain characteristic changes that occur from the earliest stages of disease, enabling early detection and offering a better way to monitor disease progression and a patient’s response to treatment.

From the company's annual report filed with the US SEC: read the report

VolitionRx Limited timeline

5 events, 1998–2025
  1. 1998
  2. 🏁
    · approximate
    Founded
  3. 1999
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2011
  6. ✎
    Renamed Volitionrx Ltd
    Formerly Standard Capital Corp.
  7. 2015
  8. 🔔
    · approximate
    Initial public offering on NYSE
  9. 2025
  10. 💰
    Record revenue of $2 million
    FY2025, the highest of the 7 years on record.

Events of VolitionRx Limited from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$52 M$104 M$156 M$207 M2020202120222023202420252026

World rank over time

▼ down 10,330 places since 2020
2020-01-01: #16083#16,08320202021-01-01: #15776#15,77620212022-01-07: #19968#19,96820222022-12-25: #19873#19,87320222023-07-30: #21824#21,82420232024-01-05: #21929#21,92920242026-03-08: #11733#11,73320262026-08-01: #23448#23,44820262026-10-06: #26201#26,20120262026-10-30: #26413#26,4132026

Rank in USA: #3,264 (Jan 2020) · #3,281 (Jan 2021) · #4,011 (Jan 2022) · #4,002 (Dec 2022) · #4,250 (Jul 2023) · #3,760 (Jan 2024) · #2,266 (Mar 2026) · #4,099 (Aug 2026) · #4,283 (Oct 2026) · #4,354 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
2.1×
Price / book
—
Free cash flow yield
-273.8%
Net margin (TTM)
-699.7%
Operating margin
-1256.6%
Return on equity
—
Liabilities / assets
615.8%
Net debt
$6M
Revenue growth
+40.7%
R&D / revenue
582.7%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-18M—FY18Fiscal year ending Dec 2019: revenue $0M, net income $-16M$0MFY19Fiscal year ending Dec 2020: revenue $0M, net income $-20M$0MFY20Fiscal year ending Dec 2021: revenue $0M, net income $-27M$0MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-31M$0MFY22Fiscal year ending Dec 2023: revenue $1M, net income $-36M$1MFY23Fiscal year ending Dec 2024: revenue $1M, net income $-27M$1MFY24Fiscal year ending Dec 2025: revenue $2M, net income $-23M$2MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$2M+40.7%$-22M$-23M-1350.3%
Dec 2024$1M+57.7%$-27M$-27M-2192.7%
Dec 2023$1M+151.6%$-36M$-36M-4574.4%
Dec 2022$0M+244.4%$-32M$-31M-9871.0%
Dec 2021$0M+800.0%$-28M$-27M-29988.9%
Dec 2020$0M-50.0%$-21M$-20M-204000.0%
Dec 2019$0M—$-16M$-16M-80500.0%
Dec 2018——$-18M$-18M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-20M$0M$-20M——
Dec 2024$-26M$0M$-26M$-0.31—
Dec 2023$-18M$1M$-19M$-0.50—
Dec 2022$-15M$2M$-17M——
Dec 2021$-21M$1M$-22M$-0.51—
Dec 2020$-16M$2M$-18M$-0.45—
Dec 2019$-13M$1M$-13M$-0.41—
Dec 2018$-15M$-0M$-14M$-0.57—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$3M
Net income, trailing 12 months
$-24M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $0M, net income $-6M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-5M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-6M$0MJun ’25Three months to Sep 2025: revenue $1M, net income $-5M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-6M$0MDec ’25Three months to Mar 2026: revenue $1M, net income $-7M$1MMar ’26Three months to Jun 2026: revenue $0M, net income $-7M$0MJun ’26Three months to Sep 2026: revenue $2M, net income $-4M$2MSep ’26

Latest quarter to Sep 2026: revenue $2M (+155.6% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of VolitionRx Limited with the US Securities and Exchange Commission.

Annual results

Revenue
$2 M
Operating income
$-22 M
Net income
$-23 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$7 M
Total liabilities
$42 M
Total equity
$-34 M

As of December-2025

Top 28 institutional investors in VolitionRx Limited#

As of Sep 30, 2026
28 institutions held 2.7 M shares (about 7.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 7.1%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in VolitionRx Limited
#InstitutionShares heldChange (shares)% heldValueFiled
1Lagoda Investment Management, L.P.1,669,686+213,736 (+14.68%)4.63%$0 MNov 16, 2026
2Luminus Management LLC425,372+268,475 (+171.12%)1.18%$0 MNov 16, 2026
3Quadrant Private Wealth Management, LLC85,000New0.24%$0 MNov 4, 2026
4Miller Financial Services LLC71,000New0.20%$0 MOct 20, 2026
5UBS Group AG50,867+46,448 (+1051.10%)0.14%$0 MNov 10, 2026
6Vanguard Capital Management LLC50,6840 (0.00%)0.14%$0 MNov 13, 2026
7Geode Capital Management, LLC50,217-5,320 (-9.58%)0.14%$0 MNov 6, 2026
8Wealthspire Advisors, LLC50,000+5,000 (+11.11%)0.14%$0 MNov 13, 2026
9Citadel Advisors LLC47,656New0.13%$0 MNov 16, 2026
10Stifel Financial Corp45,050New0.12%$0 MNov 12, 2026
11XTX Topco Ltd35,347+9,966 (+39.27%)0.10%$0 MNov 16, 2026
12State Street Corp33,680-315 (-0.93%)0.09%$0 MNov 12, 2026
13Vanguard Fiduciary Trust Co25,1330 (0.00%)0.07%$0 MNov 13, 2026
14BlackRock, Inc.19,087-3,221 (-14.44%)0.05%$0 MNov 13, 2026
15StoneX Group Inc.14,589New0.04%$0 MNov 3, 2026
16Northern Trust Corp12,9780 (0.00%)0.04%$0 MNov 16, 2026
17Silverberg Bernstein Capital Management LLC10,636-1,884 (-15.05%)0.03%$0 MOct 13, 2026
18Tower Research Capital LLC (TRC)5,922+154 (+2.67%)0.02%$0 MNov 16, 2026
19Northwestern Mutual Wealth Management Co1,9990 (0.00%)0.01%$0 MNov 13, 2026
20SBI Securities Co., Ltd.750+562 (+298.94%)0.00%$0 MOct 22, 2026
21Hickory Point Bank & Trust250New0.00%$0 MOct 1, 2026
22Jones Financial Companies Lllp150New0.00%$0 MNov 13, 2026
23Morgan Stanley310 (0.00%)0.00%$0 MNov 13, 2026
24Royal Bank Of Canada31New0.00%$0 MNov 16, 2026
25Osaic Holdings, Inc.210 (0.00%)0.00%$0 MNov 12, 2026
Show all 28: investors 26 to 28
Institutional investors 26 to 28 in VolitionRx Limited
#InstitutionShares heldChange (shares)% heldValueFiled
26Group One Trading LLC20-2,480 (-99.20%)0.00%$0 MNov 10, 2026
27BNP Paribas Financial Markets140 (0.00%)0.00%$0 MNov 12, 2026
28Caitong International Asset Management Co., Ltd10 (0.00%)0.00%$0 MOct 29, 2026

Mutual funds holding VolitionRx Limited#

5 funds hold shares worth $0 M (about 0.3% of the company). Since their previous reports 5 added shares and 0 sold, buying $0 M net.
Mutual funds holding VolitionRx Limited
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC31,776$0 M0.09%<0.01%newMay 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.50,684$0 M0.14%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC7,037$0 M0.02%<0.01%newMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC5,775$0 M0.02%<0.01%newMay 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC588$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 5 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at VolitionRx Limited#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
30
since
$254 K-$18 K$0Nov 2023: bought $53 K (5 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $29 K (4 trades), sold $15 K (1 trades)Jan 2024: bought $0 (0 trades), sold $18 K (1 trades)Jan 24Aug 2024: bought $101 K (1 trades), sold $0 (0 trades)Dec 2024: bought $254 K (4 trades), sold $0 (0 trades)DecMar 2025: bought $100 K (2 trades), sold $0 (0 trades)May 2025: bought $30 K (2 trades), sold $0 (0 trades)MayJun 2025: bought $18 K (2 trades), sold $0 (0 trades)Aug 2025: bought $50 K (2 trades), sold $0 (0 trades)AugSep 2025: bought $10 K (1 trades), sold $0 (0 trades)Oct 2025: bought $130 K (3 trades), sold $0 (0 trades)OctNov 2025: bought $7 K (1 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
VolitionRx Limited: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Ann-Louise BatchelorGroup Chief Marketing OfficerGrant or award+12,000——27,786Form 4
filed Gaetan MichelChief Operating OfficerShares withheld for tax-608$0.250$15212,232Form 4
filed Gael ForterreChief Commercial OfficerShares withheld for tax-284$0.250$7116,284Form 4
filed Jacob Vincent MicallefChief Scientific OfficerShares withheld for tax-5,310$0.190$1 K572,179Form 4
filed Nicholas PlummerGC - Volition DiagnosticsShares withheld for tax-7,003$0.190$1 K407,267Form 4
filed Rodney Gerard RootsaertSecretaryShares withheld for tax-3,948$0.190$750273,993Form 4
filed Gael ForterreChief Commercial OfficerShares withheld for tax-5,251$0.190$998331,338Form 4
filed Rodney Gerard RootsaertSecretaryShares withheld for tax-3,321$0.210$697277,941Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: VolitionRx Limited#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.4 M
22.2% of shares · 1.19 days to cover
Buybacks, Q4 2024
$0M
Q4 2024
Shares sold short, last 24 reportsAll stocks →
VolitionRx Limited share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2024Q4 2024$0M
Q3 2024Q3 2024$0M
Q2 2024Q2 2024$0M
Q1 2024Q1 2024$0M
Q4 2023Q4 2023$0M
Q3 2023Q3 2023$0M
Q2 2023Q2 2023$0M
Q1 2023Q1 2023$0M
Q4 2022Q4 2023$0M
Q3 2022Q3 2023$0M
Q2 2022Q2 2023$0M
Q1 2022Q1 2023$0M

Fails to deliver

  • : 42,025 shares at $0.20
  • : 469 shares at $0.19
  • : 31,836 shares at $0.18
  • : 10,857 shares at $0.17
  • : 15,377 shares at $0.17

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

VolitionRx Limited scorecard#

Passes 5 of the 15 checks that could be worked out: strongest in growth (4 of 5), weakest in financial health (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median2.1×Price to sales 2.1× against Diagnostics and Research's median of 4.5×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth4 of 5
    • ✓Revenue grew in the newest year40.6%Revenue up 40.6% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years77.4%77.4% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median77.4%77.4% a year against Diagnostics and Research's median of 3.6% (64 companies).
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$23 M-$23 M in fiscal 2025 against -$20 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$23 MNet income -$23 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.2×Current ratio 0.17 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-63.13Z-score -63.13 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year23.5%Diluted shares up 23.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

VolitionRx Limited: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

VolitionRx Limited: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue1.71.20.80.30.10.00.0———
Research and development10142015r13r1510118.0r7.9r
Selling and marketing3.95.46.86.63.7r1.11.01.20.8r0.3
General and administrative9.58.51010r12r5.74.75.85.8r4.2r
Operating expenses232837322821161815r12r
Operating income−22−27−36−32−28−21−16−18−15r−12r
Interest expense and finance costs————0.20.10.1r−0.1r0.10.0
Other non-operating income (expense)−1.8−0.20.31.21.30.8−0.1−0.1——
Net income including minority interests−24−27−36—−27−20−16−18——
Minority interests' share of net income—−0.3−0.4r0.3——————
Net income attributable to shareholders−23−27r−36−31−27−20−16−18−15−12
Earnings per share, basic————-0.51-0.45-0.41-0.57-0.56-0.52
Earnings per share, diluted—-0.31-0.50—-0.51-0.45-0.41-0.57-0.56-0.52
Shares, weighted average (diluted)1078771—534539312623
Balance sheet
Cash and cash equivalents1.13.32111211917131022
Receivables0.30.10.20.10.00.00———
Other current assets0.20.30.40.40.80.60.30.20.20.2
Current assets2.14.12212222018141122
Property, plant and equipment4.04.45.55.44.95.23.03.13.52.1
Right-of-use (leased) assets0.50.60.50.60.40.30.4———
Other intangible assets0.30.30.00.10.20.30.40.50.60.6
Total assets6.99.42818272621171525
Accounts payable2.92.83.23.01.51.50.60.80.40.3
Debt due within a year0.90.91.21.10.80.80.60.40.40.0
Current liabilities127.88.9r176.56.23.92.32.32.0
Long-term debt5.84.03.62.82.32.62.22.01.30.4
Lease liabilities (non-current)0.30.40.40.40.2r0.2r0.1———
Non-current liabilities30284.84.0———3.0——
Total liabilities423637219.89.97.15.34.73.6
Retained earnings−253−230−203−167−137−110−90−74−56−41
Shareholders' equity−34−25−7.8−2.6r18r16141210.021
Minority interests−1.3−1.2−0.9−0.6−0.2—————
Total equity−36−26−8.7−3.11816r14———
Total liabilities and equity6.99.42818272621171525
Shares outstanding6.3r968258544941352726
Cash-flow statement
Depreciation and amortization1.01.11.20.90.90.70.70.60.50.3
Share-based compensation1.71.32.33.1r2.51.41.52.62.41.7
Cash from operating activities−20−26−18−15−21−16−13−15−12−8.9r
Capital expenditure−0.1−0.3−1.1−1.6−1.0−1.9−0.5r−0.3r−1.4−0.4
Intangible assets bought0−0.3————————
Cash from investing activities−0.1−0.6−1.1−1.6−1.0−1.6−0.5−0.3−1.4−0.4
Debt issued2.01.41.91.5——0.81.21.2—
Debt repaid−0.9−1.1−1.0−1.3——−0.4−0.4——
Shares issued118.6286.7232117171.025
Shares bought back—0−0.00——————
Cash from financing activities178.7296.9232117182.025r
Exchange-rate effect on cash0.50.30.00.20.1−0.0−0.10.40.1−0.1
Change in cash−2.1−179.9−9.71.12.53.53.3−1216
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at VolitionRx Limited#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Directors and officers 3 · Material agreement 9 · Unregistered share sale 8 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 6

VolitionRx Limited: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Results announced8-K
Material agreement8-K
Unregistered share sale8-K
Unregistered share sale8-K
Unregistered share sale8-K
Material agreement8-K
Unregistered share sale8-K
Results announced8-K
Unregistered share sale8-K
Bylaws or fiscal year changedShareholder vote8-K
Unregistered share sale8-K
Material agreement8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Delisting notice8-K
Shareholder vote8-K
Results announced8-K
Unregistered share sale8-K
Delisting notice8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Material agreement8-K/A
Results announced8-K
Material agreement8-K/A
Material agreement8-K
Material agreementResults announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of VolitionRx Limited
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2025$23 MPrivate placement after listing$10 to $50 million1debt, optionsSEC
Aug 2018$24 MPrivate placement after listing$10 to $50 million1equity, optionsSEC
Sep 2014$1 MNo. 3Under $2 million7equitySEC
Feb 2014$3 MNo. 2$2 to $10 million24equity, optionsSEC
Apr 2012$1 MNo. 1Under $2 million33equity, optionsSEC
Oct 2011$2 MIssued in a merger or acquisitionUnder $2 million38equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How VolitionRx Limited compares in Diagnostics and Research

  • Market cap$7 M · higher than 9% of 110
  • Revenue$2 M · higher than 7% of 123
  • Net margin-699.7% · higher than 0% of 112
  • Revenue growth40.6% · higher than 90% of 89
  • Price / sales2.1× · lower than 69% of 85

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
VolitionRx Limited🇺🇸$7 M—-699.7%+40.6%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at VolitionRx Limited? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show VolitionRx Limited's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about VolitionRx Limited? Suggest a correction